Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Dec 19, 2025

Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation
Dec 15, 2025

Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis

• Ongoing discussions with the FDA regarding nrSPMS application have indicated regulatory decision for tolebrutinib is anticipated to be delayed
Nov 7, 2025

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
Nov 4, 2025

ASH: new data reinforce Sanofi’s leadership in rare diseases and blood cancers
Oct 22, 2025

Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.